

<b>Effective Date: 07/1/2021</b>
Reviewed: 4/2021, 3/2022, 4/2022, 4/2024, 4/2025, 06/2026
Scope: Medicaid

## VERQUVO (vericiguat)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Verquvo is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. CRITERIA FOR APPROVAL

An authorization may be granted when all the following criteria are met:

- The requested drug is being prescribed to reduce the risk of cardiovascular death and heart failure hospitalization in an adult member with symptomatic chronic heart failure of NYHA class II-IV; AND
- Medication is being prescribed or in consultation with a cardiologist; AND
- The member is at least 18 years of age; AND
- Documentation that member has a left ventricular ejection fraction (LVEF) less than 45 percent; AND
- The dose does not exceed 10 mg/day; AND
- The member is currently receiving optimal therapy for heart failure management (e.g., angiotensin-converting enzyme inhibitor [ACEI], angiotensin II receptor blocker [ARB], angiotensin receptor-neprilysin inhibitor [ARNI], beta-blocker); AND
- If the request is not for continuation of therapy, the member has had one of the following:
  - A) Hospitalization for heart failure within the past 6 months OR
  - B) Use of outpatient intravenous (IV) diuretics for heart failure within the past 3 months

#### III. DOSING LIMITS

- 1 tablet / day

<b>Effective Date: 07/1/2021</b>
Reviewed: 4/2021, 3/2022, 4/2022, 4/2024, 4/2025, 06/2026
Scope: Medicaid

#### IV. COVERAGE DURATION

- 1 year

#### V. REFERENCES

1. Verquvo [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; January 2026. Accessed June 2026.
2. Lexicomp Online, Lexi-Drugs Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed January 2021.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed January 2021.
4. Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. Published online January 2021. Available at: [https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022?\\_ga=2.266943758.1073019511.1611765807-2024013049.1611765807](https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022?_ga=2.266943758.1073019511.1611765807-2024013049.1611765807)